What is the Share Price of Piramal Pharma Ltd?
- Answer Field
-
The share price of Piramal Pharma Ltd for NSE is ₹ 211.05 and for BSE is ₹ 211.05.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, PIRAMAL PHARMA LIMITED share price is currently at ₹ 211.05, which is down by ₹ -0.91 from its previous closing. Today, the stock has fluctuated between ₹ 209.26 and ₹ 216.37. Over the past year, PIRAMAL PHARMA LIMITED has achieved a return of 46.91 %. In the last month alone, the return has been -6.42 %. Read More...
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 1248.32 |
Operating Expense | 1113.61 |
Net Profit | 118.80 |
Net Profit Margin (%) | 9.51 |
Earnings Per Share (EPS) | 0.90 |
EBITDA | 244.04 |
Effective Tax Rate (%) | 25.47 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 19.60 | 1.99 | 279.41 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 119.00 | 15.60 | 1.24 | 1253.91 | 92.25 / 184.95 |
CIPLA LTD | 1549.65 | 25.08 | 4.41 | 125155.99 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 260.70 | 21.60 | 2.64 | 767.27 | 145.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 21.96 | 6.19 | 279.41 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 692.80 | 40.61 | 6.72 | 2002.93 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8665.50 | 129.24 | 31.88 | 21663.75 | 5000.00 / 9199.00 |
BLISS GVS PHARMA LTD | 119.00 | 15.45 | 1.22 | 1253.91 | 92.25 / 184.95 |
Particulars | Sep 2024 (₹ Cr) | Jun 2024 (₹ Cr) | Mar 2024 (₹ Cr) | Dec 2023 (₹ Cr) | Sep 2023 (₹ Cr) |
---|---|---|---|---|---|
Revenue | 1284.39 | 1063.20 | 1525.30 | 1024.14 | 994.24 |
Operating Expense | 1115.06 | 988.30 | 1215.82 | 967.58 | 987.13 |
Net Profit | 210.06 | 85.27 | 273.08 | 74.34 | 77.16 |
Net Profit Margin (%) | 16.35 | 8.02 | 17.90 | 7.25 | 7.76 |
Earnings Per Share (EPS) | 1.59 | 0.64 | 2.06 | 0.56 | 0.61 |
EBITDA | 359.27 | 188.39 | 442.83 | 158.64 | 175.24 |
Effective Tax Rate (%) | 23.81 | 23.63 | 24.70 | 17.08 | 19.78 |
Key Highlights
Particulars | Value (₹ Cr) |
---|---|
Revenue | 4390.11 |
Operating Expense | 4084.54 |
Net Profit | 391.22 |
Net Profit Margin (%) | 8.91 |
Earnings Per Share (EPS) | 3.05 |
EBITDA | 819.98 |
Effective Tax Rate (%) | 22.93 |
Key Highlights
Particulars | Value |
---|---|
Dividend Yield | 0.04% |
Earnings Per Share (EPS) | ₹3.05 |
Net Profit | ₹391.22 Cr |
Piramal Pharma Share Price | ₹273.45 |
Key Highlights
Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market.
PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.
Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. The global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions.
In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL).
In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA).
In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs.
On 7th October 2021, the Composite Scheme of Arrangement, which was entered into between the Company, Piramal Enterprises Limited, Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to Company, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of the Company) into Company; and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL became effective from August 18, 2022.
In consideration for the demerger, the equity shareholders of PEL as on the demerger record date received 4 equity shares of face and paid-up value of Rs 10 each of the Company for every 1 equity share of face and paid-up value of Rs 2 each held in PEL. i.e. 4:1. Accordingly, the Company was listed on the Stock Exchanges, BSE Limited (BSE) and National Stock Exchange of India Limited 'NSE) on October 19, 2022.
In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an India-Based CDMO providing expertise in biologics and vaccines. It launched 26 New products and 37 new SKUs during FY 2023.
In FY24, Company launched 27 new products and 24 new SKUs .
The share price of Piramal Pharma Ltd for NSE is ₹ 211.05 and for BSE is ₹ 211.05.
The market cap of Piramal Pharma Ltd for NSE is ₹ 2,79,20.82 Cr. and for BSE is ₹ 2,79,20.82 Cr. as of now.
The 52 Week High and Low of Piramal Pharma Ltd for NSE is ₹ 307.90 and ₹ 136.10 and for BSE is ₹ 307.85 and ₹ 135.85.
You can trade in Piramal Pharma Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been 46.91%.
Piramal Pharma Ltd share price is for NSE ₹ 211.05 & for BSE ₹ 211.05 as on Apr 30 2025 03:30 PM.
The market cap of Piramal Pharma Ltd for NSE ₹ 2,79,20.82 & for BSE ₹ 2,79,20.82 as on Apr 30 2025 03:30 PM.
As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Piramal Pharma Ltd share is 40.74.
As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Piramal Pharma Ltd share is 52.94.
You can trade in Piramal Pharma Ltd shares with Bajaj Broking by opening a demat account.
To buy Piramal Pharma Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Piramal Pharma Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found